Results 171 to 180 of about 7,364,456 (335)

β‐TrCP overexpression enhances cisplatin sensitivity by depleting BRCA1

Molecular Oncology, EarlyView.
Low levels of β‐TrCP (Panel A) allow the accumulation of BRCA1 and CtIP, which facilitate the repair of cisplatin‐induced DNA damage via homologous recombination (HR) and promote tumor cell survival. In contrast, high β‐TrCP expression (Panel B) leads to BRCA1 and CtIP degradation, impairing HR repair, resulting in persistent DNA damage and apoptosis ...
Rocío Jiménez‐Guerrero, Alejandro Belmonte‐Fernández, Mónica González‐Moreno, Laura Rodríguez‐Cordero, Begoña Pérez‐Valderrama, Joaquín Herrero‐Ruíz, Francisco Romero, Carmen Sáez, Miguel Á. Japón   +8 more
wiley   +1 more source

Fluorination of Silver Phosphate in Nickel Reaction Vessels for Triple Oxygen Isotope Analysis. [PDF]

Rapid Commun Mass Spectrom
Wostbrock JAG, Yarian D, Chiaravalloti I, Moller SR, Blake RE.   +4 more
europepmc   +1 more source

Nicotinamide N‐methyltransferase promotes drug resistance in lung cancer, as revealed by nascent proteomic profiling

Molecular Oncology, EarlyView.
AZD9291 has shown promise in targeted cancer therapy but is limited by resistance. In this study, we employed metabolic labeling and LC–MS/MS to profile time‐resolved nascent protein perturbations, allowing dynamic tracking of drug‐responsive proteins. We demonstrated that increased NNMT expression is associated with drug resistance, highlighting NNMT ...
Zhanwu Hou, Zhen Wang, Fei Yang, Xiao Han, Lei Li, Huadong Liu   +5 more
wiley   +1 more source

Stable Carbon and Oxygen Isotope Analysis of Carbonates and DIC Using the Delta Ray Isotope Ratio Infrared Spectrometer (IRIS): Precise and Accurate Measurements Applying a 3-Point Calibration and Standard Bracketing. [PDF]

Rapid Commun Mass Spectrom
Hansen M, Brettschneider J, Vonhof H, Scholz D.   +3 more
europepmc   +1 more source

First Passage Analysis of the Folding of a β-Sheet Miniprotein: Is it More Realistic Than the Standard Equilibrium Approach? [PDF]

, 2014
Igor V. Kalgin, S. F. Chekmarev, Martin Karplus   +2 more
openalex   +1 more source

PARP inhibitors elicit distinct transcriptional programs in homologous recombination competent castration‐resistant prostate cancer

Molecular Oncology, EarlyView.
PARP inhibitors are used to treat a small subset of prostate cancer patients. These studies reveal that PARP1 activity and expression are different between European American and African American prostate cancer tissue samples. Additionally, different PARP inhibitors cause unique and overlapping transcriptional changes, notably, p53 pathway upregulation.
Moriah L. Cunningham, Jasibel Vasquez‐Gonzalez, Samantha M. Barnada, Salome Tchotorlishvili, Latese Jones, Ryan Maguire, Genevieve Lewis, Kinza Rizwan, Jenny Deng, Salma Koachar, Drithi Patel, Hailey Shankle, Tessa Mulders, Namra Ajmal, Charalambos Solomides, Emad S. Alnemri, Teresa F. Alnemri, Ayesha A. Shafi, Leonard G. Gomella, Wm Kevin Kelly, Steven B. McMahon, Matthew J. Schiewer   +21 more
wiley   +1 more source

Teachers’ standards [PDF]

, 2011

core  

Response to "Toward Audit-Ready Standards for Synthetic Cohorts in Health Decision Science". [PDF]

Health Data Sci
Ferreira G, Amidei J, Nieto R, Kaltenbrunner A.   +3 more
europepmc   +1 more source

Results of a Phase III Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial (CORRECT) of Regorafenib Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Patients with Metastatic Colorectal Cancer (MCRC) who have Progressed after Standard Therapies

, 2012
Takayuki Yoshino, Eric Van Cutsem, Alberto Sobrero, Salvatore Siena, Alfredo Falcone, Marc Ychou, Heinz‐Josef Lenz, Frank Cihon, Thierry André, Axel Grothey   +9 more
openalex   +1 more source

One loop predictions of the finely tuned supersymmetric standard model [PDF]

, 2004
Asimina Arvanitaki, Chad Davis, Peter W. Graham, Jay G. Wacker   +3 more
openalex   +1 more source